Strategies to optimize analgesia and sedation

Table 1 Outcomes between patients randomized to intermittent bolus lorazepam versus propofol with daily interruption

	Lorazepam	Propofol	P
Ventilator days
All patients	8.4 (4.6, 14.7)	5.8 (3.5, 10.3)	0.04
Survivors	9.0 (5.3, 16.8)	4.4 (3.0, 8.7)	0.006
Nonsurvivors	7.5 (4.0, 11.4)	7.2 (4.2, 13.2)	0.66
28-day ventilator-free survival (days)
All patients	10.2 (0, 20)	18.5 (0, 24)	0.06
ICU length of stay (days)
All patients	10.4 (6.7, 16.8)	8.3 (5.2, 15.2)	0.20
Survivors	12.7 (7.8, 19.1)	8.6 (5.0, 14.7)	0.05
Nonsurvivors	9.5 (5.3, 12.0)	9.3 (6.0, 18.1)	0.68
Hospital length of stay (days)
All patients	20 (12, 30)	18 (12, 29)	0.55
Survivors	22.5 (14, 33)	19 (10, 32)	0.16
Hospital mortality (n [%])	24 (38)	25 (37)	0.82

The total numbers of patients were 64 for the lorazepam group and 68 for the propofol group. Respectively, 40 and 43 patients survived ('survivors'), and 24 and 25 patients did not survive ('nonsurvivors'). Unless otherwise stated, values are expressed as median (25th, 75th percentiles). ICU, intensive care unit. Adapted with permission from Carson SS, Kress JP, Rodgers JE, Vinayak A, Campbell-Bright S, Levitt J, Bourdet S, Ivanova A, Henderson AG, Pohlman A, et al.: A randomized trial of intermittent lorazepam versus propofol with daily interruption in mechanically ventilated patients. Crit Care Med 2006, 34(5):1326–1332.

ISSN: 1364-8535